These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6416794)

  • 1. Immunotherapy and immune competence of patients with malignant melanoma.
    Kovarík J; Ninger E; Mechl Z; Zemanová D; Lauerová L; Sopková B; Svejda J; Bacovský B; Bártová A; Bártek J
    Czech Med; 1983; 6(3):172-4. PubMed ID: 6416794
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress of immunotherapy in the treatment of malignant melanoma.
    Ariyan S
    Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B; Wätzig V; Knöll B
    Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 6. [Possibilities of immunotherapy in malignant melanoma].
    Lewis MG
    Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunological factors which influence response to immunotherapy in malignant melanoma.
    Morton D; Eilber FR; Malmgren RA; Wood WC
    Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction of melanoma specific monocyte cytotoxicity in patients receiving BCG immunotherapy.
    Dufour FD; Morton DL
    Surg Forum; 1977; 28():165-7. PubMed ID: 617405
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 13. [Basis for a specific-active immunotherapy in malignant melanoma].
    Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
    Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer immunotherapy in dermatological view (author's transl)].
    Lübbe D; Gstöttner R
    Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BCG-treatment of malignant melanoma].
    Borberg H
    Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254
    [No Abstract]   [Full Text] [Related]  

  • 16. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of immunotherapy in the treatment of malignant melanoma of the skin].
    Kristensen E
    Ugeskr Laeger; 1976 Feb; 138(8):468-73. PubMed ID: 1258215
    [No Abstract]   [Full Text] [Related]  

  • 18. Low doses of chemotherapy to inhibit suppressor T cells.
    Berd D
    Prog Clin Biol Res; 1989; 288():449-58. PubMed ID: 2566177
    [No Abstract]   [Full Text] [Related]  

  • 19. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local active immunotherapy for malignant melanoma.
    Serrou B; Dubois JB; Meiss L; Romieu C
    Panminerva Med; 1975; 17(5-6):182-6. PubMed ID: 1161316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.